The effect of the pandemic period on Bladder Pain Syndrome patients under amitriptyline treatment

被引:2
|
作者
Sahin, Mehmet Fatih [1 ,5 ]
Ozcan, Ridvan [2 ]
Malak, Arzu [3 ]
Dogan, Cagri [4 ]
Yazici, Cenk Murat [4 ]
Ozcan, Muege [4 ]
Akgul, Murat [4 ]
机构
[1] Corlu State Hosp, Dept Urol, Corlu, Tekirdag, Turkiye
[2] Bursa City Hosp, Dept Urol, Bursa, Nilufer, Turkiye
[3] Tekirdag Namik Kemal Univ, Sch Hlth, Nursing Dept, Suleymanpasa, Tekirdag, Turkiye
[4] Tekirdag Namik Kemal Univ, Med Sch, Dept Urol, Suleymanpasa, Tekirdag, Turkiye
[5] Corlu State Hosp, Dept Urol, TR-59850 Corlu, Tekirdag, Turkiye
关键词
anxiety; bladder pain syndrome; COVID-19; depression; INTERSTITIAL CYSTITIS; ANXIETY; WOMEN;
D O I
10.1002/nau.25199
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
IntroductionCOVID-19 is a disease that may cause anxiety, depression, and stress. Bladder pain syndrome (BPS) is a disease in which stress and psychological factors might negatively affect its course. In this study, we aimed to examine the possible clinical aggregation of the pandemic period on BPS patients. Materials and MethodsA total of 35 BPS patients diagnosed between 2010 and 2018 were included. All patients were using medical treatment, and the follow-up period was at least 6 months. According to our clinical follow-up protocol, the BPS patients were given the King's Health Questionnaire (KHQ), Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI), Overactive Bladder Form V8 (OAB-V8), and Visual Analog Score (VAS) in every visit. In the sixth month of the pandemic, the clinical course of the patients was questioned by telephone or video interview, and their treatment continuities were questioned. Information was received about the delays in their follow-up and the difficulties in accessing healthcare opportunities. The same questionnaires were filled out and compared with pre-pandemic scores. ResultsThe mean age of the patients included in the study was 50.2 +/- 13.32 (min:20, max:74), 11 were males and 24 were females. The mean follow-up periods were 71.8 +/- 35.6 months. All questionnaire scores showed an increase compared to the pre-pandemic period. A statistically significant increase was detected during the pandemic in all sub-units of the KHQ. The VAS and OAB-V8 scores of 16 patients who requested hospital admission were significantly higher than before the pandemic. However, there was no statistically significant difference in the increase in VAS and OAB-V8 scores of the 19 patients who refused to come to the hospital. ConclusionBPS patients have been negatively affected by the emotional effects of the COVID-19 pandemic. Due to the fear, stress, anxiety, and depression, the symptoms of BPS patients exacerbated, and the patients could not receive the necessary support due to a lack of regular follow-ups.
引用
收藏
页码:1188 / 1193
页数:6
相关论文
共 50 条
  • [41] Anxiety severity does not influence treatment outcomes in patients with interstitial cystitis/bladder pain syndrome
    Yu, Wan Ru
    Peng, Tai Chu
    Yeh, Hui Ling
    Kuo, Hann-Chorng
    NEUROUROLOGY AND URODYNAMICS, 2019, 38 (06) : 1602 - 1610
  • [42] COMPARISON OF CYSTISTAT®, iALURIL®, AND WHITMORE COCKTAIL FOR TREATMENT OF PATIENTS WITH BLADDER PAIN SYNDROME/INTERSTITIAL CYSTITIS
    Cocci, A.
    Hashim, H.
    JOURNAL OF SEXUAL MEDICINE, 2016, 13 (05): : S230 - S230
  • [43] ANXIETY SCORE DOES NOT INFLUENCE TREATMENT OUTCOME IN PATIENTS WITH INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME
    Yu, W.
    Yeh, H.
    Kuo, H.
    NEUROUROLOGY AND URODYNAMICS, 2018, 37 : S121 - S122
  • [44] Treatment Outcomes of Intravesical Botulinum Toxin A Injections on Patients with Interstitial Cystitis/Bladder Pain Syndrome
    Yu, Wan-Ru
    Jiang, Yuan-Hong
    Jhang, Jia-Fong
    Chang, Wei-Chuan
    Kuo, Hann-Chorng
    TOXINS, 2022, 14 (12)
  • [45] Onabotulinumtoxin a injection with or without hydrodistension for treatment of bladder pain syndrome
    Mateu Arrom, Laura
    Gutierrez Ruiz, Cristina
    Palou, Joan
    Errando-Smet, Carlos
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2021, 32 (05) : 1213 - 1219
  • [46] Treatment of bladder pain syndrome and interstitial cystitis: a systematic review
    Pazin, Carolina
    de Souza Mitidieri, Andreia Moreira
    Moreira Silva, Ana Paula
    Ferreira Gurian, Maria Beatriz
    Poli-Neto, Omero Benedicto
    Rosa-e-Silva, Julio Cesar
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2016, 27 (05) : 697 - 708
  • [47] Treatment of bladder pain syndrome and interstitial cystitis: a systematic review
    Carolina Pazin
    Andréia Moreira de Souza Mitidieri
    Ana Paula Moreira Silva
    Maria Beatriz Ferreira Gurian
    Omero Benedicto Poli-Neto
    Julio Cesar Rosa-e-Silva
    International Urogynecology Journal, 2016, 27 : 697 - 708
  • [48] Onabotulinumtoxin a injection with or without hydrodistension for treatment of bladder pain syndrome
    Laura Mateu Arrom
    Cristina Gutierrez Ruiz
    Joan Palou
    Carlos Errando-Smet
    International Urogynecology Journal, 2021, 32 : 1213 - 1219
  • [49] INTRAVESICAL TACROLIMUS IN TREATMENT OF BLADDER PAIN SYNDROME/INTERSTITIAL CYSTITIS
    Mishra, Nagendra Nath
    JOURNAL OF UROLOGY, 2016, 195 (04): : E317 - E318
  • [50] Effects of Low-Dose Amitriptyline on Epigastric Pain Syndrome in Functional Dyspepsia Patients
    Liu, Jing
    Jia, Lin
    Jiang, Shu-man
    Zhou, Wen-cong
    Liu, Yao
    Xu, Jian
    DIGESTIVE DISEASES AND SCIENCES, 2021, 66 (02) : 521 - 525